The FDA has granted Allos Therapeutics (NASDAQ: ALTH) next-generation chemotherapy drug pralatrexate, or PDX, for the treatment of T-cell lymphoma, with an orphan drug designation. An orphan drug designation is assigned to a drug that targets the treatment of a disease with less than 200,000 sufferers in the U.S. The status provides seven years of [...]